AU2022392456A1 - Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma - Google Patents

Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma Download PDF

Info

Publication number
AU2022392456A1
AU2022392456A1 AU2022392456A AU2022392456A AU2022392456A1 AU 2022392456 A1 AU2022392456 A1 AU 2022392456A1 AU 2022392456 A AU2022392456 A AU 2022392456A AU 2022392456 A AU2022392456 A AU 2022392456A AU 2022392456 A1 AU2022392456 A1 AU 2022392456A1
Authority
AU
Australia
Prior art keywords
composition
nitroxoline
use according
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022392456A
Other languages
English (en)
Inventor
David Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of AU2022392456A1 publication Critical patent/AU2022392456A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022392456A 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma Pending AU2022392456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116743.2 2021-11-19
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (1)

Publication Number Publication Date
AU2022392456A1 true AU2022392456A1 (en) 2024-05-23

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022392456A Pending AU2022392456A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
JP2024540439A (ja) 2024-10-31
CA3238805A1 (en) 2023-05-25
MX2024006105A (es) 2024-05-30
KR20240108407A (ko) 2024-07-09
CN118215479A (zh) 2024-06-18
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01
GB202116743D0 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
US20250000852A1 (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
ES2403006T3 (es) Antagonistas de la vía Hedgehog para tratar enfermedades
Ding et al. Inhibition of dectin-1 alleviates neuroinflammatory injury by attenuating NLRP3 inflammasome-mediated pyroptosis after intracerebral hemorrhage in mice: preliminary study results
Chen et al. A brain-penetrating Hsp90 inhibitor NXD30001 inhibits glioblastoma as a monotherapy or in combination with radiation
EP2968379A1 (en) Etoposide and prodrugs thereof for use in targeting cancer stem cells
Min et al. Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-κB/MAPK signaling pathway
Radin et al. Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo
Kim et al. Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models
Kim et al. Nucleocytoplasmic p27Kip1 export is required for ERK1/2-mediated reactive astroglial proliferation following status epilepticus
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
Rizzo et al. Radiation therapy for glioma stem cells
US20210023104A1 (en) Use of ginsenoside m1 for manufacturing medicament for treating oral cancer
US10864182B2 (en) Treatment of fragile X syndrome
Lin et al. Antipsychotic Zuclopenthixol inhibits melanoma growth and brain metastasis by inducing apoptosis and cell cycle arrest
Sezginer et al. Remifentanil induces apoptosis and G1-phase cell cycle arrest in human MCF-7 breast cancer cells
WO2022175671A1 (en) Trifluoperazine for use in the treatment of neurobéastoma
AU2023391325A1 (en) Nitroxoline for use in the treatment or prevention of a malignant peripheral nerve sheath tumour
WO2022175670A1 (en) Lovastatin for use in the treatment of neuroblastoma
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
CN108175769A (zh) 土贝母苷甲在制备治疗类风湿性关节炎药物中的应用
WO2022175673A1 (en) Prochlorperazine for use in the treatment of neuroblastoma
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
WO2026065486A1 (zh) Quisinostat在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途